Ebola

• The CDC is currently responding to Ebola disease outbreaks occurring in the Democratic Republic of the Congo (DRC) and Uganda. • The agency has issued specific health guidance and monitoring information for travelers returning to the United States from the DRC, Uganda, and South Sudan. • These measures are critical to prevent the domestic spread of the virus and ensure that returning travelers receive immediate medical screening if symptoms appear.

• Biotech companies including Soligenix, Moderna, Regeneron, and Aethlon Medical are accelerating the development of vaccines and therapeutics to combat a global outbreak of Bundibugyo ebolavirus in 2026. • Regeneron's maftivimab, a potent antibody found in the FDA-approved Inmazeb, has been recommended by the WHO's Therapeutics Advisory Group for use in clinical trials. • Aethlon Medical (Nasdaq:AEMD) is preparing to coordinate with global health authorities to deploy its Hemopurifier device as part of the medical response.

Fears over ‘huge, huge community transmission’ as modelling predicts thousands of cases and deaths by SeptemberThe whereabouts of almost 300 people who have tested positive for Ebola in the Democratic Republic of the Congo is currently unknown, according to Africa’s top public health official.The humanitarian crisis amid the conflict in the affected areas means more than 1 million people are living in camps to which health workers have no access, Dr Jean Kaseya, director general of the Africa Centers for Disease Control and Prevention (CDC), said on Thursday. Continue reading...

• The UN's top humanitarian official has allocated $8 million to assist Burundi and South Sudan in preparing for the potential spread of Ebola. • Despite increased laboratory capacity from the WHO and Africa CDC, the UN is urging donors to provide more funding to sustain life-saving humanitarian assistance. • UNICEF issued a statement of condolence after an explosive device in the village of Raybi, Yemen, killed five children and injured seven others.

• WHO Director-General Tedros Adhanom Ghebreyesus announced that clinical trials for two experimental drugs will launch next week in the Democratic Republic of the Congo. • The trials will evaluate whether the antivirals MBP134 and remdesivir, provided via donations from the United States and Gilead Sciences, can reduce mortality rates. • This intervention is critical because the Bundibugyo strain of Ebola currently has no approved vaccines or therapeutics, and this is only the third such outbreak in history.

FDA's early-stage clinical trial program, a mysterious single patient gets retatrutide access, and more health news from Morning Rounds

A clinical trial testing two drugs against the Bundibugyo ebolavirus, which is driving a fast-moving outbreak in Central Africa, is set to begin next week, WHO officials said.